By SPC News Staff
The FDA granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics [GBT]) for the treatment of sickle cell disease (SCD) in adults and children aged 12 years and older.
NOVEMBER 26, 2019
NOVEMBER 26, 2019
By SPC News Staff
The FDA granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics [GBT]) for the treatment of sickle cell disease (SCD) in adults and children aged 12 years and older.